Abstract Number: 1762 • 2017 ACR/ARHP Annual Meeting
Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Background/Purpose: ETS Proto-oncogene 1, transcription factor (ETS1) is a transcription factor involved in immune responses. Genome-wide association studies on systemic lupus erythematosus (SLE) in Chinese…Abstract Number: 1763 • 2017 ACR/ARHP Annual Meeting
Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry
Background/Purpose: Diagnosing ANCA-associated vasculitides (AAVs) can be challenging. Their clinical presentations are numerous and the time to diagnosis may range from days to years.1,2 The…Abstract Number: 1764 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Background/Purpose: MicroRNAs (miRNAs) are small RNA molecules (~22 nucleotides) that participate in post-transcriptional gene regulation. miRNAs have potential both as biomarkers for diagnosis and prognosis…Abstract Number: 1765 • 2017 ACR/ARHP Annual Meeting
Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis
Background/Purpose: The purpose of this study was to validate the recently proposed ACR EULAR 2017 classification criteria of GPA in a real life cohort of…Abstract Number: 1766 • 2017 ACR/ARHP Annual Meeting
Increased Renal Damage in Hypocomplementemic Patients with ANCA- Associated Vasculitis
Background/Purpose: The pauci-immune nature of typical lesions in ANCA associated vasculitis (AAV) has led to the belief that complement does not play a role in…Abstract Number: 1767 • 2017 ACR/ARHP Annual Meeting
The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months
Background/Purpose: Standard management of ANCA-associated vasculitis (AAV) involves treatment with immunosuppressive agents for at least 18 months. Treatment beyond 18 months reduces the rates of…Abstract Number: 1768 • 2017 ACR/ARHP Annual Meeting
Cocaine and ANCA Associated Vasculitis-like Syndromes – a Case Series
Background/Purpose: Cocaine is a potent illicit stimulant and may trigger a ÔpseudovasculitisÕ mimicking idiopathic ANCA vasculitis. We describe the clinical and serological manifestations of patients…Abstract Number: 1769 • 2017 ACR/ARHP Annual Meeting
Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study
Background/Purpose: In patients with microscopic polyangiitis (MPA), a variety of pulmonary lesions including diffuse alveolar hemorrhage (DAH), airways disease and interstitial lung disease (ILD) have…Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management
Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting
Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…Abstract Number: 1772 • 2017 ACR/ARHP Annual Meeting
Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?
Background/Purpose: Protocolized and non-protocolized repeat renal biopsies are rarely performed in ANCA glomerulonephritis. Their role in predicting long term renal outcomes and aiding in clinical…Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting
New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis
Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…Abstract Number: 1774 • 2017 ACR/ARHP Annual Meeting
Serum Periostin As a Biomarker in Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Identification of a biomarker to predict relapse in eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss) would enhance the ability to personalize treatment options and improve…Abstract Number: 1775 • 2017 ACR/ARHP Annual Meeting
The Utility of the ACR/EULAR 2017 Provisional Classification Criteria for Granulomatosis with Polyangiitis in Korean Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: We applied the ACR/ EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis (GPA) to 150 Korean patients with previously diagnosed Antineutrophil cytoplasmic antibody…Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
ACR Meeting Abstracts